Anavex Life Sciences Corp. (AVXL)
1.15
+0.04
(+3.60%)
USD |
NASDAQ |
Nov 06, 16:00
1.145
0.00 (0.00%)
After-Hours: 20:00
Anavex Life Sciences Research and Development Expense (Quarterly) : -4.705M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.705M |
| March 31, 2026 | 4.192M |
| December 31, 2025 | 4.656M |
| September 30, 2025 | 7.295M |
| June 30, 2025 | 9.959M |
| March 31, 2025 | 9.892M |
| December 31, 2024 | 10.45M |
| September 30, 2024 | 11.56M |
| June 30, 2024 | 11.81M |
| March 31, 2024 | 9.729M |
| December 31, 2023 | 8.684M |
| September 30, 2023 | 10.06M |
| June 30, 2023 | 10.28M |
| March 31, 2023 | 11.31M |
| December 31, 2022 | 12.07M |
| September 30, 2022 | 11.38M |
| June 30, 2022 | 9.273M |
| March 31, 2022 | 8.605M |
| December 31, 2021 | 8.656M |
| September 30, 2021 | 9.373M |
| June 30, 2021 | 8.964M |
| March 31, 2021 | 6.721M |
| December 31, 2020 | 7.926M |
| September 30, 2020 | 6.105M |
| June 30, 2020 | 6.725M |
| Date | Value |
|---|---|
| March 31, 2020 | 6.053M |
| December 31, 2019 | 6.349M |
| September 30, 2019 | 4.711M |
| June 30, 2019 | 5.758M |
| March 31, 2019 | 6.079M |
| December 31, 2018 | 5.712M |
| September 30, 2018 | 4.408M |
| June 30, 2018 | 2.998M |
| March 31, 2018 | 3.245M |
| December 31, 2017 | 2.694M |
| September 30, 2017 | 3.836M |
| June 30, 2017 | 2.300M |
| March 31, 2017 | 2.493M |
| December 31, 2016 | 2.042M |
| September 30, 2016 | 4.339M |
| June 30, 2016 | 0.9173M |
| March 31, 2016 | 1.327M |
| December 31, 2015 | 0.6707M |
| September 30, 2015 | 0.7465M |
| June 30, 2015 | 0.7995M |
| March 31, 2015 | 0.4071M |
| December 31, 2014 | 0.3186M |
| September 30, 2014 | 0.344M |
| June 30, 2014 | 0.265M |
| March 31, 2014 | 0.1182M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Vaxcyte, Inc. | 270.33M |
| Foghorn Therapeutics, Inc. | 18.32M |
| Connect Biopharma Holdings Ltd. | 16.27M |
| Caribou Biosciences, Inc. | 21.35M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |